KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis
TSX:GUD - Toronto Stock Exchange - CA4990531069 - Common Stock - Currency: CAD
We assign a fundamental rating of 4 out of 10 to GUD. GUD was compared to 34 industry peers in the Pharmaceuticals industry. While GUD seems to be doing ok healthwise, there are quite some concerns on its profitability. GUD is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year GUD was profitable.
GUD had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GUD reported negative net income in multiple years.
Of the past 5 years GUD 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.10%, GUD is in the better half of the industry, outperforming 73.53% of the companies in the same industry.
With a decent Return On Equity value of 1.39%, GUD is doing good in the industry, outperforming 70.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.1% | ||
| ROE | 1.39% | ||
| ROIC | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 2.97%, GUD is doing good in the industry, outperforming 73.53% of the companies in the same industry.
In the last couple of years the Profit Margin of GUD has declined.
GUD's Gross Margin of 44.95% is fine compared to the rest of the industry. GUD outperforms 64.71% of its industry peers.
In the last couple of years the Gross Margin of GUD has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 2.97% | ||
| GM | 44.95% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.
GUD has less shares outstanding than it did 1 year ago.
The number of shares outstanding for GUD has been reduced compared to 5 years ago.
The debt/assets ratio for GUD has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.65 indicates that GUD is not a great score, but indicates only limited risk for bankruptcy at the moment.
GUD's Altman-Z score of 2.65 is amongst the best of the industry. GUD outperforms 88.24% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that GUD is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.04, GUD is in the better half of the industry, outperforming 73.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.65 |
ROIC/WACCN/A
WACC8.99%
2.3 Liquidity
A Current Ratio of 2.97 indicates that GUD has no problem at all paying its short term obligations.
GUD has a better Current ratio (2.97) than 76.47% of its industry peers.
GUD has a Quick Ratio of 2.06. This indicates that GUD is financially healthy and has no problem in meeting its short term obligations.
GUD has a Quick ratio of 2.06. This is in the better half of the industry: GUD outperforms 79.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.97 | ||
| Quick Ratio | 2.06 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 168.75% over the past year.
Measured over the past years, GUD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.46% on average per year.
GUD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.21%.
Measured over the past years, GUD shows a very strong growth in Revenue. The Revenue has been growing by 50.87% on average per year.
EPS 1Y (TTM)168.75%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%150%
Revenue 1Y (TTM)12.21%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%2.66%
3.2 Future
Based on estimates for the next years, GUD will show a very strong growth in Earnings Per Share. The EPS will grow by 43.93% on average per year.
Based on estimates for the next years, GUD will show a small growth in Revenue. The Revenue will grow by 7.89% on average per year.
EPS Next Y13.52%
EPS Next 2Y29.64%
EPS Next 3Y17.35%
EPS Next 5Y43.93%
Revenue Next Year9.9%
Revenue Next 2Y10.12%
Revenue Next 3Y7.13%
Revenue Next 5Y7.89%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 54.00, which means the current valuation is very expensive for GUD.
GUD's Price/Earnings ratio is a bit cheaper when compared to the industry. GUD is cheaper than 70.59% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.34, GUD is valued quite expensively.
GUD is valuated quite expensively with a Price/Forward Earnings ratio of 70.69.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GUD indicates a somewhat cheap valuation: GUD is cheaper than 70.59% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.19. GUD is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54 | ||
| Fwd PE | 70.69 |
4.2 Price Multiples
GUD's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. GUD is cheaper than 73.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 8.9 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GUD does not grow enough to justify the current Price/Earnings ratio.
GUD's earnings are expected to grow with 17.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.99
PEG (5Y)N/A
EPS Next 2Y29.64%
EPS Next 3Y17.35%
5. Dividend
5.1 Amount
No dividends for GUD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:GUD (6/18/2025, 7:00:00 PM)
5.94
-0.13 (-2.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners10.02%
Inst Owner ChangeN/A
Ins Owners1.85%
Ins Owner ChangeN/A
Market Cap591.80M
Analysts81.82
Price Target7.71 (29.8%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)413.66%
Min EPS beat(2)365.93%
Max EPS beat(2)461.4%
EPS beat(4)2
Avg EPS beat(4)132.08%
Min EPS beat(4)-199.01%
Max EPS beat(4)461.4%
EPS beat(8)4
Avg EPS beat(8)-95.81%
EPS beat(12)7
Avg EPS beat(12)-39.29%
EPS beat(16)8
Avg EPS beat(16)-307.68%
Revenue beat(2)2
Avg Revenue beat(2)4.98%
Min Revenue beat(2)0.88%
Max Revenue beat(2)9.08%
Revenue beat(4)4
Avg Revenue beat(4)4.99%
Min Revenue beat(4)0.88%
Max Revenue beat(4)9.08%
Revenue beat(8)7
Avg Revenue beat(8)4.9%
Revenue beat(12)11
Avg Revenue beat(12)9.21%
Revenue beat(16)14
Avg Revenue beat(16)10.57%
PT rev (1m)0%
PT rev (3m)6.65%
EPS NQ rev (1m)-4.78%
EPS NQ rev (3m)-40.18%
EPS NY rev (1m)0%
EPS NY rev (3m)-31.46%
Revenue NQ rev (1m)-1.6%
Revenue NQ rev (3m)7.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 54 | ||
| Fwd PE | 70.69 | ||
| P/S | 1.59 | ||
| P/FCF | N/A | ||
| P/OCF | 65.26 | ||
| P/B | 0.74 | ||
| P/tB | 1.37 | ||
| EV/EBITDA | 8.9 |
EPS(TTM)0.11
EY1.85%
EPS(NY)0.08
Fwd EY1.41%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.09
OCFY1.53%
SpS3.74
BVpS7.98
TBVpS4.34
PEG (NY)3.99
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.1% | ||
| ROE | 1.39% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 2.97% | ||
| GM | 44.95% | ||
| FCFM | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
F-Score6
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.6 | ||
| Cap/Depr | 46.41% | ||
| Cap/Sales | 6.49% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 18.42% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.97 | ||
| Quick Ratio | 2.06 | ||
| Altman-Z | 2.65 |
F-Score6
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)40.08%
Cap/Depr(5y)130.51%
Cap/Sales(3y)6.77%
Cap/Sales(5y)24.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.75%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%150%
EPS Next Y13.52%
EPS Next 2Y29.64%
EPS Next 3Y17.35%
EPS Next 5Y43.93%
Revenue 1Y (TTM)12.21%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%2.66%
Revenue Next Year9.9%
Revenue Next 2Y10.12%
Revenue Next 3Y7.13%
Revenue Next 5Y7.89%
EBIT growth 1Y-220.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year371.57%
EBIT Next 3Y73.66%
EBIT Next 5Y50.37%
FCF growth 1Y-653.06%
FCF growth 3YN/A
FCF growth 5Y23.85%
OCF growth 1Y-71.04%
OCF growth 3Y-6.66%
OCF growth 5Y51.14%